Pembrolizumab induced bulbar myopathy and respiratory failure with necrotizing myositis of the diaphragm Pembrolizumab, an anti-PD 1 antibody, has been approved for the treatment of metastatic melanoma [1, 2] , non-small cell lung carcinoma [3, 4] , and head and neck cancers [5] ; and is being investigated in other cancers. We describe a case of Pembrolizumab induced severe bulbar myopathy and respiratory failure with necrotizing myositis of the diaphragm.
1:61 440, while anti-acetylcholine receptor antibody, anti-SRP70 (signal recognition particle), anti-HMGCR (3-hydroxy-3-methylglutaryl-coenzyme A reductase), and other paraneoplastic antibodies were negative. MRI of the cervical spine revealed symmetric enhancement of the paraspinal musculature. Electromyography showed reduced compound muscle action potential amplitudes in the spinal accessory and facial nerves without decrement or facilitation, contrary to the subtle facilitation on physical exam. Fibrillation potentials were noted in proximal muscle groups and in the orbicularis oculi muscles. These findings were consistent with ongoing muscle necrosis without evidence of a neuromuscular junction disorder. A triceps muscle biopsy showed necrotic fibers in most fascicles, replaced by mononuclear cells (Figure 2A ). Taken together, the elevated CK, electromyography findings, laboratory studies, and the results of the muscle biopsy favored a diagnosis of an immune-mediated necrotizing myopathy over a NMJ disorder.
Prednisone was initiated at 1 mg/kg soon after the muscle biopsy was performed and he was discharged to the outpatient setting with prednisone the following day given stability of symptoms during the 3-day hospital stay. However, a week after discharge, he was readmitted with worsening bulbar myopathy and respiratory weakness. Despite the progressive weakness, his CK was normal, suggesting that the striational antibodies may have had a pathogenic role rather than a mere response to leaked myocytoplasmic antigens. He was initiated on PLEX (given two reports of its efficacy in immunotherapy associated necrotizing myopathy [6, 7] ) and underwent three sessions, but continued to deteriorate. On hospital day 3, he was emergently intubated due to worsening respiratory weakness and mucous plugging leading to hypoxic respiratory failure. Amidst discussions of potential additional immunosuppressive therapy versus comfort care, the patient and his family requested terminal extubation given the severe deterioration and the underlying malignancy; and he passed away shortly thereafter. An autopsy was performed, which revealed diffuse necrotic myositis of the diaphragm ( Figure 2B ) and lymphohistiocytic myocarditis ( Figure 2C ). This was cited as the cause of death. No viable tumor was identified at the metastatic sites during the autopsy. These regions showed significant treatment effect, characterized by a predominantly cytotoxic T-cell population ( Figure 2D ).
This case highlights the importance of early diagnosis and recognition of the clinical course of necrotizing myopathy with immunotherapy. Given the fatal nature of this adverse effect and the potential to progress rapidly, we recommend close monitoring even in patients with a mild onset of symptoms and earlier aggressive up-titration of immunosuppression despite the theoretical risk of inhibiting the activity of anti-PD1 therapy against the underlying cancer. Pulse dose steroids, PLEX and IVIg could be initiated early and sequentially within a few days of refractoriness. In persistently refractory patients, proteasome inhibitors such as Bortezomib to deplete plasma cells and autoantibodies, or calcineurin inhibitors to inhibit cytotoxic T cells may be a consideration. With the increasing use of immunotherapy in the treatment of cancer, this approach may significantly reduce morbidity and mortality from this fatal albeit rare adverse effect. 
